Home LiteratureArticle Details
PMID: 21285512 Published · ppublish English Journal Article Research Support, N.I.H., Extramural

Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation.

The Journal of clinical investigation ·Vol. 121 ·No. 3 ·2011-03-00 ·Pages 893-904

Wang Y, Suh YA, Fuller MY, Jackson JG, Xiong S, Terzian T, Quintás-Cardama A, Bankson JA, El-Naggar AK, Lozano G

Abstract

The transcription factor p53 is a tumor suppressor. As such, the P53 gene is frequently altered in human cancers. However, over 80% of the P53 mutations found in human cancers are missense mutations that lead to expression of mutant proteins that not only lack p53 transcriptional activity but exhibit new functions as well. Recent studies show that restoration of p53 expression leads to tumor regression in mice carrying p53 deletions. However, the therapeutic efficacy of restoring p53 expression in tumors containing p53 missense mutations has not been evaluated. Here we demonstrate that restoring wild-type p53 expression halted tumor growth in mice inheriting a p53(R172H) missense mutation that is equivalent to a P53 missense mutation detected in approximately 6% of human cancers. However, it did not lead to tumor regression, as was observed in mice lacking p53. We further showed that the dominant-negative effect of the mutant p53 encoded by p53(R172H) dampened the activity of the restored wild-type p53. We therefore conclude that in a mutant p53 background, p53 restoration has the therapeutic potential to suppress tumor progression. Our findings support using p53 restoration as a strategy to treat human cancers with P53 missense mutations and provide direction for optimizing p53 restoration in cancer therapy.

MeSH Terms
3T3 Cells Alleles Animals Female Gene Deletion Gene Expression Regulation, Neoplastic Genes, Dominant Genes, Tumor Suppressor Genes, p53 Introns Magnetic Resonance Imaging Male Mice Mice, Inbred C57BL Mutation, Missense Neoplasms/genetics,therapy Transcription, Genetic Tumor Suppressor Protein p53/genetics
Chemicals
Tumor Suppressor Protein p53
Authors & Affiliations
10 authors, click to expand affiliations / ORCID
Wang Yongxing
Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Suh Young-Ah
Fuller Maren Y
Jackson James G
Xiong Shunbin
Terzian Tamara
Quintás-Cardama Alfonso
Bankson James A
El-Naggar Adel K
Lozano Guillermina
References (41)
41 references, click to expand
  1. High metastatic potential in mice inheriting a targeted p53 missense mutation.
    Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4174-9 PMID: 10760284
  2. Mutant p53 is not fully dominant over endogenous wild type p53 in a colorectal adenoma cell line as demonstrated by induction of MDM2 protein and retention of a p53 dependent G1 arrest after gamma irradiation.
    Oncogene. 1995 Jul 6;11(1):141-9 PMID: 7624121
  3. Restoration of p53 function leads to tumour regression in vivo.
    Nature. 2007 Feb 8;445(7128):661-5 PMID: 17251932
  4. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53.
    Nature. 1995 Nov 9;378(6553):206-8 PMID: 7477327
  5. Adenovirus p53 gene therapy.
    Expert Opin Biol Ther. 2006 Jan;6(1):55-61 PMID: 16370914
  6. Efficient recombination in diverse tissues by a tamoxifen-inducible form of Cre: a tool for temporally regulated gene activation/inactivation in the mouse.
    Dev Biol. 2002 Apr 15;244(2):305-18 PMID: 11944939
  7. Dosage-dependent dominance over wild-type p53 of a mutant p53 isolated from nasopharyngeal carcinoma.
    FASEB J. 1993 Jul;7(10):944-50 PMID: 8344492
  8. A biomarker that identifies senescent human cells in culture and in aging skin in vivo.
    Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9363-7 PMID: 7568133
  9. Cancer gene therapy: an awkward adolescence.
    Cancer Gene Ther. 2003 Jul;10(7):501-8 PMID: 12833130
  10. Why did p53 gene therapy fail in ovarian cancer?
    Lancet Oncol. 2003 Jul;4(7):415-22 PMID: 12850192
  11. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound.
    Nat Med. 2002 Mar;8(3):282-8 PMID: 11875500
  12. Mdm2 and Mdm4 loss regulates distinct p53 activities.
    Mol Cancer Res. 2008 Jun;6(6):947-54 PMID: 18567799
  13. Primary and compensatory roles for RB family members at cell cycle gene promoters that are deacetylated and downregulated in doxorubicin-induced senescence of breast cancer cells.
    Mol Cell Biol. 2006 Apr;26(7):2501-10 PMID: 16537896
  14. How loops, beta sheets, and alpha helices help us to understand p53.
    Cell. 1994 Aug 26;78(4):543-6 PMID: 8069906
  15. Intrinsic tumour suppression.
    Nature. 2004 Nov 18;432(7015):307-15 PMID: 15549092
  16. Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies.
    Oncogene. 1991 Sep;6(9):1699-703 PMID: 1923535
  17. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53.
    Nature. 1995 Nov 9;378(6553):203-6 PMID: 7477326
  18. Transactivational and DNA binding abilities of endogenous p53 in p53 mutant cell lines.
    Oncogene. 1994 Jul;9(7):1899-906 PMID: 8208536
  19. Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation.
    Cell. 1991 May 31;65(5):765-74 PMID: 2040013
  20. Exploiting the p53 pathway for the diagnosis and therapy of human cancer.
    Cold Spring Harb Symp Quant Biol. 2005;70:489-97 PMID: 16869788
  21. Gene therapy progress and prospects: cancer gene therapy using tumour suppressor genes.
    Gene Ther. 2004 Mar;11(6):497-503 PMID: 14762396
  22. An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2.
    Oncogene. 2001 Jul 5;20(30):4041-9 PMID: 11494132
  23. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.
    Cancer Res. 1994 Sep 15;54(18):4855-78 PMID: 8069852
  24. The oncogenic roles of p53 mutants in mouse models.
    Curr Opin Genet Dev. 2007 Feb;17(1):66-70 PMID: 17208429
  25. Dominance of wild-type p53-mediated transcriptional activation in breast epithelial cells.
    Oncogene. 1996 Sep 19;13(6):1315-22 PMID: 8808706
  26. p53 induced growth arrest versus apoptosis and its modulation by survival cytokines.
    Cell Cycle. 2007 Jan 15;6(2):166-70 PMID: 17264673
  27. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations.
    Science. 1994 Jul 15;265(5170):346-55 PMID: 8023157
  28. Haploinsufficiency of Mdm2 and Mdm4 in tumorigenesis and development.
    Mol Cell Biol. 2007 Aug;27(15):5479-85 PMID: 17526734
  29. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database.
    Hum Mutat. 2007 Jun;28(6):622-9 PMID: 17311302
  30. P53 is a tumor suppressor gene.
    Cell. 2004 Jan 23;116(2 Suppl):S67-9, 1 p following S69 PMID: 15055586
  31. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome.
    Cell. 2004 Dec 17;119(6):847-60 PMID: 15607980
  32. Comparative binding of p53 to its promoter and DNA recognition elements.
    J Mol Biol. 2005 May 6;348(3):589-96 PMID: 15826656
  33. P53 promoter selection: choosing between life and death.
    Cell Cycle. 2008 Jan 15;7(2):154-7 PMID: 18212532
  34. PUMA, a novel proapoptotic gene, is induced by p53.
    Mol Cell. 2001 Mar;7(3):683-94 PMID: 11463392
  35. Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase II study.
    J Clin Oncol. 2001 Mar 15;19(6):1750-8 PMID: 11251006
  36. The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss.
    Genes Dev. 2008 May 15;22(10):1337-44 PMID: 18483220
  37. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome.
    Cell. 2004 Dec 17;119(6):861-72 PMID: 15607981
  38. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas.
    Nature. 2007 Feb 8;445(7128):656-60 PMID: 17251933
  39. Modeling the therapeutic efficacy of p53 restoration in tumors.
    Cell. 2006 Dec 29;127(7):1323-34 PMID: 17182091
  40. Chromatin immunoprecipitation analysis fails to support the latency model for regulation of p53 DNA binding activity in vivo.
    Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):95-100 PMID: 11756653
  41. A phase I study of adenovirus-mediated wild-type p53 gene transfer in patients with advanced non-small cell lung cancer.
    Hum Gene Ther. 1998 Sep 20;9(14):2075-82 PMID: 9759934
Article Info
Journal
The Journal of clinical investigation
Abbr.
J Clin Invest
ISSN
1558-8238
Published
2011-03-00
Pages
893-904
Language
English
Region
United States
NLM ID
7802877
PMCID
PMC3049366
Subset
IM
Grants
NCI NIH HHS · P30 CA016672 · United States
NCI NIH HHS · R01 CA082577-13 · United States
NCI NIH HHS · R01 CA082577 · United States
NCI NIH HHS · CA34936 · United States
NCI NIH HHS · CA82577 · United States
NCI NIH HHS · P01 CA034936 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com